Annual Review | Dr. Yao Zhu: Advances in Surgical Diagnosis and Treatment of Prostate Cancer in 2024

Annual Review | Dr. Yao Zhu: Advances in Surgical Diagnosis and Treatment of Prostate Cancer in 2024

As 2024 concludes, the field of minimally invasive urological surgery has made remarkable strides, particularly in prostate cancer surgery, which often serves as a testing ground for innovative surgical approaches. With the advancement of precision medicine and multidisciplinary team (MDT) management, prostate cancer surgery now extends beyond simple tumor removal, incorporating preoperative diagnostic optimization, postoperative systemic therapy, and alternative local treatment approaches. In this annual review, Dr. Yao Zhu from Fudan University Shanghai Cancer Center summarizes the key developments in prostate cancer surgery over the past year.
Dr. Anqin Zhang: Current Status, Challenges, and Future Directions for Breast Cancer Screening in Young Women | 2024 Yixian Breast Cancer Conference

Dr. Anqin Zhang: Current Status, Challenges, and Future Directions for Breast Cancer Screening in Young Women | 2024 Yixian Breast Cancer Conference

The increasing prevalence of breast cancer among younger women poses significant challenges for early detection and treatment. At the 2024 Yixian Breast Cancer Conference and the 2nd China Young Breast Cancer Consensus Conference, Dr. Anqin Zhang from Guangdong Women and Children’s Hospital provided an in-depth analysis of the current status and issues surrounding breast cancer screening in younger populations. In an interview with Oncology Frontier, Professor Zhang shared insights from his extensive clinical experience and the latest research, addressing the challenges of breast cancer screening for young women, recommending effective screening methods, and proposing strategies to enhance participation and outcomes.

Dr. Yaping Yang: Characteristics and Personalized Treatment Strategies for Young Breast Cancer Patients | 2024 Yixian Breast Cancer Conference

Editorial Note: The 2024 Yixian Breast Cancer Conference and the 2nd China Young Breast Cancer Consensus Conference, held on December 27–28 in Guangzhou, focused on cutting-edge topics such as the changing epidemiology of young breast cancer, screening strategies, the impact of genetic mutations, treatment, and rehabilitation. During the conference, Dr. Yaping Yang from Sun Yat-sen Memorial Hospital delivered a lecture on “Genetic Mutations in Young Breast Cancer Patients,” addressing key issues such as the impact of genetic mutations on cure rates and whether routine referrals to breast specialists are necessary for BRCA-mutated ovarian cancer patients. In an interview with Oncology Frontier, Professor Yang discussed the characteristics of young breast cancer patients and provided personalized treatment recommendations for those carrying genetic mutations.
Annual Review | Academician Binghe Xu: Advances in Systemic Therapy for HR+/HER2- Breast Cancer in 2024

Annual Review | Academician Binghe Xu: Advances in Systemic Therapy for HR+/HER2- Breast Cancer in 2024

Editor’s Note: Breast cancer remains the leading cause of cancer-related deaths among women worldwide, with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer being the most common molecular subtype. In recent years, targeted therapies, antibody-drug conjugates (ADCs), and selective estrogen receptor degraders (SERDs) have propelled this subtype into the era of precision medicine. Looking back at 2024, what breakthroughs and conceptual shifts have occurred in the systemic treatment of HR+/HER2- breast cancer? Oncology Frontier invited Academician Binghe Xu from the Cancer Hospital Chinese Academy of Medical Sciences and the Chinese Academy of Engineering to provide an overview and summary.
Annual Review | Dr. Xiaofan Zhu: Advances in Pediatric ALL and AML in 2024

Annual Review | Dr. Xiaofan Zhu: Advances in Pediatric ALL and AML in 2024

In 2024, significant progress was made in the field of pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), bringing new insights and advancements to clinical practice. These studies covered innovations in treatment approaches, evaluations of drug efficacy, and a deeper understanding of the biological characteristics of these diseases. These findings are crucial for advancing precision medicine in pediatric leukemia and improving patient outcomes.